tiprankstipranks
Cannara Biotech Reports Record Growth in 2024
Company Announcements

Cannara Biotech Reports Record Growth in 2024

Story Highlights
  • Cannara Biotech achieved a 43% increase in annual revenue and a 3.2% national market share.
  • The company plans to expand its production capacity with new grow zones in 2025.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Cannara Biotech (TSE:LOVE) has released an update.

Don't Miss our Black Friday Offers:

Cannara Biotech Inc. has reported record-breaking sales growth and operating cash flow for fiscal 2024, achieving a 43% increase in annual revenue and a 3.2% national market share. The company’s strong financial performance, marked by a 14th consecutive quarter of positive Adjusted EBITDA and significant improvements in free cash flow, underscores its robust position in Canada’s cannabis market. Looking ahead, Cannara plans to expand its production capacity with new grow zones in 2025, aiming to further strengthen its market standing.

For further insights into TSE:LOVE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyMacy’s uncovers employee fraud, Summit to be acquired: Morning Buzz
TheFlyCannara Biotech reports Q4 EPS C$0.06 vs. C$0.05 last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App